瑞舒伐他汀治疗对代谢综合征患者的影响

The Effects of Different Doses of Oral Rosuvastatin Treatment on Patients with Metabolic Syndrome

目的探讨口服不同剂量的瑞舒伐他汀治疗对代谢综合征患者血脂、血管内皮功能及炎性因子的影响。方法整群选择该院在2012年6月—2015年3月所收治代谢综合征患者122例作为研究对象,按照入院顺序随机分为两组,观察组60例,服用瑞舒伐他汀20 mg每晚1次。对照组62例,采取常规治疗。观察12周,监测相关指标的变化。结果两组治疗12周后较治疗前:总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、内皮素(ET)、高敏C反应蛋白(hs-CRP)均有明显降低,治疗12周后,观察组的TC(5.4±0.6)mmol/L、TG(2.6±0.4)mmol/L、HDL-C(1.07±0.2)mmol/L、ET(46.8±4.7)ng/L、hs-CRP(25.7±4.8)mg/L明显较对照组的TC(5.6±0.6)mmol/L、TG(2.8±0.5)mmol/L、HDL-C(1.12±0.2)mmol/L、ET(54.6±5.3)ng/L、hs-CRP(30.6±5.2)mg/L更低,差异有统计学意义(P<0.05);观察组的CK(136.1±61.2)U/L、AST(23.2±7.9)U/L、ALT(24.9±8.0)U/L与对照组的CK(136.5±58.7)U/L、AST(22.1±8.1)U/L、ALT(23.2±8.2)U/L相比,差异无统计学意义(P>0.05)。结论瑞舒伐他汀对代谢综合征患者均有调脂、抗炎、改善血管内皮功能的作用,其大剂量有更强的调脂、抗炎、改善血管内皮功能的作用,但肌损害、肝损害的副作用并未增加。

Objective To observe effects of different doses of oral rosuvastatin treatment on blood lipids, vascular endothelial function and inflammatory factors in patients with metabolic syndrome. Methods Group selection choose 122 cases of patients with metabolic syndrome,were randomly divided into two groups： observation group of 60 cases, taking rosuvastatin20 mg one time a night. Control group 62 cases, and taking rosuvastatin 10 mg one time a night.12 weeks observation, monitoring the change of relevant indicators. Results 12 weeks after treatment than before treatment： total cholesterol（TC）,triglyceride（TG）, low density lipoprotein cholesterol（LDL-C）, endothelin（ET）, high-sensitivity C-reactive protein（hs-CRP）were have significantly reduced after 12 weeks of treatment, TC observation group（5.4±0.6） mmol/L, TG（2.6±0.4） mmol/L,HDL-C（1.07 ± 0.2） mmol/L, ET（46.8±4.7） ng/L, hs-CRP（25.7 ± 4.8） mg/L significantly higher than the TC in the control group（5.6 ± 0.6） mmol/L, TG（2.8±0.5） mmol/L, HDL-C（1.12±0.2） mmol/L, ET（54.6±5.3） ng/L, hs-CRP（30.6 ± 5.2） mg / L lower, the difference was statistically significant（P〈0.05）; CK observation group（136.1±61.2） U/L, AST（23.2 ± 7.9） U / L,ALT（24.9 ± 8.0） U/L and control group（136.5±58.7） U/L, AST（22.1±8.1） U/L, ALT（23.2±8.2） U/L also no significant difference, the difference was not statistically significant（P〉0.05）. Conclusion Different doses of oral rosuvastatin treatment possessed the effects of lipid-lowering,anti-inflammatory and improving endothelial function in patients with metabolic syndrome.and high-dose of oral rosuvastatin treatment had the stronger effects of lipid-lowering,anti-inflammatory and improving endothelial function, but it did not increase the side effects of muscle damage and liver damage.